目的 通过挖掘Oncomine和GEO基因芯片数据库中的相关数据，分析信号调节蛋白α（SIRPα）基因在乳腺癌中的表达及其临床意义，并探讨丹参酚酸B对乳腺癌细胞中SIRPα基因的干预作用。方法 检索Oncomine和GEO数据库中有关乳腺癌和丹参酚酸B干预乳腺癌的数据集，对所获取的数据资料进行数据挖掘，并结合文献资料综合分析。考察丹参酚酸B作用于乳腺癌MCF7细胞的基因表达谱。结果 对Oncomine数据库中共收集的9项关于乳腺癌和乳腺正常组织SIRPα基因有差异表达的研究数据进行分析，发现乳腺癌组织中SIRPα基因的表达明显低于乳腺正常组织，差异具有统计学意义（P<0.05）。通过生存分析发现低表达SIRPα基因乳腺癌患者无病生存期明显差于高表达者，高表达患者的预后更好（P<0.05）。通过挖掘GEO数据库中的数据集GSE85871发现丹参酚酸B能够上调乳腺癌细胞SIRPα基因的表达（P<0.01）。结论 SIRPα基因在乳腺癌组织中呈现低表达，并与乳腺癌患者的预后相关，该基因可能是丹参酚酸B干预乳腺癌细胞的一个新靶点。

Objective To analyze the expression and its clinical significance of signal regulatory protein α (SIRPα) gene in breast cancer through mining the related microarray data from Oncomine and GEO database, and to explore the effects of salvianolic acid B on the expression of SIRPα in breast cancer cells. Methods The datasets about breast cancer and effects of salvianolic acid B on breast cancer cell were retrieved from Oncomine and GEO database, and then the datasets were deeply mined and analyzed with literature. Gene expression profiles of salvianolic acid B against breast cancer MCF7 cells were investigated. Results The mRNA expressions of SIRPα gene in breast carcinoma tissues were significantly lower than those of breast normal tissues through mining and analyzing the 9 datasets about SIRPα gene in breast carcinoma from Oncomine database (P< 0.05). Survival analysis showed that the disease-free survival of breast cancer patients with higher expression of SIRPα gene was significantly worse than that of patients with lower expression of SIRPα, and the prognosis of patients with low expression of SIRPα gene was better (P < 0.05). The mRNA expression of SIRPα gene was down-regulated by salvianolic acid B in the datasets of GSE85871 through mining the GEO database (P< 0.01). Conclusion SIRPα gene is under-expressed in breast cancer and its expression level is related with the prognosis of breast cancer, which may be a new target of effects of salvianolic acid B on breast cancer cells.

国家自然科学基金资助项目（81704023、81602535）；湖北省卫计委中西医结合科研一般项目（23）；武汉市卫计委科研项目（WZ15Z07）